Search results
Results from the WOW.Com Content Network
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for ...
For premium support please call: 800-290-4726 more ways to reach us
Here's why tomorrow could be a big day for the stock market. Economic data over the coming months could play a big role in determining how the market performs in the near term and in 2025.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
That puts the stock market in a precarious position. Expectations regarding rate cuts could change based on an important economic data point that will be published on Wednesday, Nov. 27.
Here's why tomorrow could be a big day for the stock market. Important economic data At 8:30 a.m. tomorrow, the U.S. Bureau of Labor Statistics will release its monthly nonfarm payrolls report for ...
IONIS-GCCR Rx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. [ 1 ] [ 2 ] It has also been under investigation for the treatment of Cushing's syndrome , but no development has been reported. [ 1 ]
But before this happens, new economic data will come out tomorrow that could move the stock market significantly and impact the U.S. presidential race. Here's why tomorrow could be a big day.